DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
WSJ’s Daniela Hernandez - 2 Eli Lilly ’ - 2 Elizabeth Smelov - 1 Ozempic - 1 Elizabeth Smelov Eli Lilly ’ - 1 Mounjaro - 1 Lilly - 1 Eli Lilly - 1
Top related locs:
Elizabeth Smelov U.S Novo Denmark’s Novo
Top related orgs:
Novo Nordisk - 2 Drug Administration - 1 Denmark’s - 1 Denmark’s Novo Nordisk - 1 NYU Langone Health - 1

Search resuls for: "Eli Lilly ’"


4 mentions found


☆ Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.
  + stars: | 2023-11-08 | by ( Peter Loftus | ) www.wsj.com   time to read: 1 min
Earlier: Some drugs initially approved to treat Type 2 diabetes are now being used for cosmetic weight loss. WSJ’s Daniela Hernandez explains how they work, their side effects, and concerns over unintended consequences. Illustration: Elizabeth SmelovU.S. drug regulators have approved expanding the use of Eli Lilly ’s diabetes drug Mounjaro to include the treatment of obesity. The Food and Drug Administration’s decision Wednesday furthers the rapid rise of Mounjaro—and similar-acting therapies Ozempic and Wegovy from Novo Nordisk —that have in a matter of months reshaped the treatment of obesity and doctors’ understanding of its roots.
Persons: WSJ’s Daniela Hernandez, Elizabeth Smelov, Eli Lilly ’, Ozempic Organizations: Novo Nordisk Locations: Elizabeth Smelov U.S, Novo
☆ Obesity Drug Demand Outstrips Supply
  + stars: | 2023-11-02 | by ( David Wainer | ) www.wsj.com   time to read: 1 min
Diabetes drugs could become an effective way to treat behavioral issues and addiction. WSJ’s Daniela Hernandez breaks down the science on how they work and how they could change psychiatry forever. Photo illustration: Elizabeth SmelovEli Lilly ’s blockbuster diabetes medication Mounjaro is expected to receive Food and Drug Administration approval as an obesity treatment before the end of the year, which would lead to a surge in demand. Whether there will be enough of the drug is a different question. Both Lilly and its competitor, Denmark’s Novo Nordisk , which makes Ozempic and its sister drug Wegovy, are struggling to meet skyrocketing demand for their medications.
Persons: WSJ’s Daniela Hernandez, Elizabeth Smelov Eli Lilly ’, Mounjaro, Lilly Organizations: Drug Administration, Denmark’s, Denmark’s Novo Nordisk Locations: Denmark’s Novo
☆ Eli Lilly experimental obesity drug helped patients lose up to 24% of their weight, study says
  + stars: | 2023-06-26 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Eli Lilly ’s experimental drug helped patients lose up to 24% of their weight after almost a year, the highest reduction seen in the obesity treatment space to date, according to new mid-stage clinical trial results released Monday. The trial's researchers said average weight loss did not appear to plateau after 48 weeks, suggesting a longer study could show even more. Eli Lilly’s other obesity drug Mounjaro, which is approved for type 2 diabetes, has helped patients lose up to 21% of their weight in clinical trials. Novo Nordisk’ s Wegovy, cleared for weight loss, has shown up to 15% weight loss in trials. But Wegovy only mimics one hunger-regulating hormone called GLP-1, while Mounjaro mimics GLP-1 and another hormone called GIP.
Persons: Eli Lilly ’, Eli Lilly, Eli Lilly’s retatrutide, ” Michael Weintraub, Eli Lilly’s, Eli Lilly's retatrutide Organizations: NYU Langone Health, Novo Nordisk
☆ Eli Lilly Results Signal Arrival of Blockbuster New Drug Class
  + stars: | 2023-05-03 | by ( David Wainer | ) www.wsj.com   time to read: 1 min
Testing on new drug donanemab showed it is effective in treating Alzheimer’s, Eli Lilly said. Photo: Maddie McGarvey for The Wall Street JournalEli Lilly ’s announcement that its experimental drug slowed declines in Alzheimer’s patients’ ability to perform daily tasks means there could soon be two drugs available on the market for people with early stages of the debilitating disease. That is great news for patients after billions of dollars and years of studies failed to produce a single treatment that could slow the disease’s progression. It is good not only for Eli Lilly but also for Biogen , whose new drug Leqembi has an accelerated approval from the Food and Drug Administration.
0 next >>
Total: 4